The need for precompetitive integrative bionetwork disease model building.
If you doubt that there are enormous gaps in the current drug discovery process, you should probably skip to the next article. Yet even while critiques rightly highlight inefficiencies or operational issues, they often miss a fundamental reality: until we better understand diseases as altered bionetworks and view diseases at an individual patient level, efforts to develop effective biomarkers and therapies will be inefficient at best.
Friend
S H
SH
Sage Bionetworks, Seattle, Washington, USA. friend@sagebase.org
D000818:Animals; D003198:Computer Simulation / Q000639:trends*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D053263:Gene Regulatory Networks / Q000235:genetics; D006801:Humans; D008957:Models, Genetic; D049490:Systems Biology / Q000379:methods / Q000639:trends; D035703:Therapies, Investigational / Q000379:methods / Q000639:trends*